AP952A - Novel erthromycin derivatives, method for preparing same, and use thereof as drugs. - Google Patents
Novel erthromycin derivatives, method for preparing same, and use thereof as drugs. Download PDFInfo
- Publication number
- AP952A AP952A APAP/P/1998/001318A AP9801318A AP952A AP 952 A AP952 A AP 952A AP 9801318 A AP9801318 A AP 9801318A AP 952 A AP952 A AP 952A
- Authority
- AP
- ARIPO
- Prior art keywords
- formula
- radical
- compounds
- methyl
- dideoxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
- C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
A subject of the invention is the compounds of formula (I) : in which: X represents a CH2 or S02 radical or an oxygen atom, Y represents a (CH2)m-(CK=CH)n(CH2)o radical, with m+n+os8, n = 0 or 1, Ar represents an aryl radical, W represents a hydrogen atom, or the remainder of a carbamate function. The compounds of formula (I) have useful antibiotic properties.
Description
New erythromycin derivatives, their preparation process and their use medicaments.
The present invention relates to new erythromycin 5 derivatives, their preparation process and their use as medicaments .
A subject of the invention is the compounds of formula (I) :
in which:
X represents a CH2 or SO2 radical or an oxygen atom, Y 25 represents a (CH2)m-(CH=CH)n(CH2)o radical, with m + n + o s 8, n = 0 or 1,
Ar represents an optionally substituted aryl radical,
W represents a hydrogen atom, or the remainder of a carbamate · |i function -C-NHRin which R represents an alkyl radical containing up to 8 carbon atoms or an optionally substituted aryl radical,
Z represents a hydrogen atom or the remainder of an acid, as 35 well as their addition salts with acids.
Among the addition salts with acids, there can be can mentioned the salts formed with the following acids: acetic, propionic, trifiuoroacetic, maleic, tartaric,
AR/F/ 9 8 0 1 3 18
AP 00952 methanesulphonic, benzenesulphonic, p-toluenesulphonic, and in particular stearic, ethylsuccinic or laurylsulphonic.
The aryl radical can be a phenyl or naphthyl .radical. The aryl radical can also be a substituted or non5 substituted heterocyclic radical such as the thienyl, furyl, pyrolyl, thiazolyl, oxazolyl, imidazolyl, thiadiazolyl, pyrazolyl or isopyrazolyl radical, a pyridyl, pyrimidyl, pyridazinyl or pyrazinyl radical, or also an indolyl benzofurannyl, benzothiazyl or quinolinyl radical.
These aryl radicals can contain one or more groups chosen from the group constituted by hydroxyl radicals, halogen atoms, NO2 radicals, C^n radicals, alkyl, alkenyl or alkynyl, 0-alkyl, 0-alkenyl or 0-alkynyl, S-alkyl, S-alkenyl or S-alkynyl and N-alkyl, N-alkenyl or N-alkynyl radicals, containing up to 12 carbon atoms optionally substituted by one or more halogen atoms, the
R / 3 N radical, Ra and Rh, identical or different, \
R representing a hydrogen atom or an alkyl radical containing up to 12 carbon atoms, the
0 £ 1 0 8 6 Idl·
-C-R3 radical, R3 representing an alkyl radical containing up to 12 carbon atoms, or an optionally substituted aryl or heteroaryl radical, the following radicals: carboxylic aryl,
0-aryl or S-aryl or heterocyclic aryl, O-aryl or S-aryl with 5 or 6 members coritaining one or more heteroatoms, optionally substituted by one or more of the substituents mentioned hereafter.
As preferred heterocycle, there can be mentioned among others:
AP 00952
N
AP/P/98 / 0 1 3 18
AP 00952
and the heterocyclic radicals envisaged in the European
Patent Applications 487411, 596802, 676409 and 680967. These preferred heterocyclic radicals can be substituted by one or more functional groups.
A more particular subject of the invention is the compounds of formula (I) in which Z represents a hydrogen atom, those in which W represents a hydrogen atom, those in which X represents a CH2 radical, those in which Y represents a (CH2)3, (CH2)4 or (CH2)5 radical.
Among the preferred compounds of the invention, there can be mentioned the compounds of formula (I), in which Ar represents a heterocyclic aryl radical, such as for example those in which Ar represents a 4-quinolinyl radical optionally mono- or polysubstituted on one and/or the other of the 2 quinoline rings, and quite particularly the compounds of formula (I) in which Ar represents a nonsubstituted 4-quinolinyl radical, or also for example the compounds of formula (I) , in which Ar represents ari optionally substituted:
AP/P/98 / 0 1 3 1®
AP 00952
radical.
Among the preferred compounds of the invention, there can naturally be mentioned the products whose preparation is given hereafter in the experimental part.
The products of general formula (I) have a very good antibiotic activity on gram + bacteria such as staphylococci, streptococci, pneumococci.
The compounds of the invention can therefore be used as medicaments in the treatment of infections caused by susceptible germs and in particular, in that of staphylococcal infections, such as staphylococcal septicemias, malignant staphylococcal infections of the face or skin, pyodermatitis, septic or suppurating sores, boils, anthrax, phlegmons, erysipelas and acne, staphylococcia such as acute primary or post-influenzal angina, bronchopneumonia, pulmonary suppuration, streptococcal infections such as acute anginas, otitis, sinusitis, scarlet fever, pneumococcal infections such as pneumonia, bronchitis; brucellosis, diphtheria, gonococcal infection.
The products of the present invention are also active against infections caused by germs such as Haemophilus influenzae, Rickettsies, Mycoplasma pneumoniae, Chlamydia, Legionella, Ureapl’asma, Toxoplasma or by germs of the Mycobacterium genus .
Therefore a subject of the present invention is, as medicaments and in particular antibiotic medicaments, the products of formula (I) as defined above, as well as their addition salts with pharmaceutically acceptable mineral or organic acids.
.W/' 9 8/01318
AP 00952
A more particular subject of the invention is, as medicaments and in particular antibiotic medicaments, the products of Examples 1 or 2 and their pharmaceutically acceptable salts.
A subject of the invention is also the pharmaceutical compositions containing at least one of the medicaments defined above as active ingredient.
These compositions can be administered by buccal, rectal, parenteral route or by local route as a topical application on the skin and mucous membranes, but the preferred administration route is the buccal route.
They can be solid or liquid and be presented in the pharmaceutical forms commonly used in human medicine, such as for example, plain or sugar-coated tablets, capsules, granules, suppositories, injectable preparations, ointments, creams, gels; they are prepared according to the usual methods. The active ingredient or ingredients can be incorporated with excipients usually employed in these pharmaceutical compositions, such as talc, gum arabic, lactose, starch, magnesium stearate, cocoa butter, aqueous or non-aqueous vehicles, fatty substances of animal or vegetable origin, paraffin derivatives, glycols, various wetting, dispersing or emulsifying agents, preservatives.
These compositions can also be presented in the form of a powder intended to be dissolved extemporaneously in an appropriate vehicle, for example apyrogenic sterile water.
The dose administered is variable according to the illness treated, the patient in question, the administration route and the product considered. It can be, for example, comprised between 50 mg and 500 mg per day by oral route, for an adult for the product of Example 1 or Example 2.
A subject of the invention is also a preparation process, characterized in that a compound of formula (II):
AP/P/98/0 1 3 18
AP 00952
in which X, Y and Ar are as defined above, is subjected to 20 the action of a cleavage agent of cladinose in order to obtain the corresponding compound of formula (IA) :
Ο H
AP 00952 in which X, Y and Ar retain their previous meaning, which is subjected, if desired, to the action of an esterification agent or to the action of an agent capable of introducing the carbamate radical.
In a preferred implementation the cleavage of cladinose in position 3 is carried out using an acid.
The products of formula (II) used as starting products, are products which can be prepared according to the process described in the European Patent Application 076093 filed on
6th December 1995 by the Company ROUSSEL UCLAF.
The products of formula (II) can be prepared according to a process characterized in that a compound of formula (III):
g I p I 0 / 81 /d/dV in which Bn represents a benzyloxycarbonyl radical and Ac an acyl radical containing 2 to 20 carbon atoms, is subjected to the action of a compound of formula (IV):
R3NH2 (IV) in which R3 represents the X-Y-Ar radical,
X, Y and Ar being defined as previously in order td obtain the compound of formula (V):
AP 00952
which is subjected., if desired, to the action of a cleavage agent of the ester function in position 2' in order to obtain the corresponding 2’-OH compound, then if desired, the compound thus obtained is subjected to the action of a reducing agent in order to carry out the cleavage of the benzyloxy carbonyl group in position 4 and to obtain the product of formula (II).
The compounds of formula (III) used as starting products ' are known products described in the European Patent 0,248,279.
The amines of formula (IV) are known in a general way and can be prepared according to the processes described in J. Med. Chem. (1982) Vol. 25, p. 947 and subsequent or also Tetrahedron Letters Vol. 32 No. 14, p. 1699, 1702 (1991).
The cleavage of the acetate in position 2' is carried out using methanol.
The cleavage of the benzyloxycarbonyl group in position 4 is carried out by reduction, for example using hydrogen in
AP/P/98 / ΰ 1 ύ 18
AP 00952 ίο the presence of a palladium catalyst.
The salification is carried out using an acid according to standard processes.
The following examples illustrate the invention without however limiting it.
EXAMPLE 1 : ll,12-dideoxy-3-de((2,6-dideoxy-3-C-niethyl-3-0methyl-alpha-L-ribohexopyranosyl)oxy)-3-hydroxy-δ-O-methyl 12,11-(oxycarbonyl(2 -(3-(4-guinolinyl)propyl)hydrazono)) erythromycin
1 cn? of a solution of hydrochloric acid in ethanol (22 g/1) is added to a solution containing 250 mg of 11,12diaeoxy-6-O-methyl-12,11-(oxycarbonyl(2-(3 -(4-guinolinyl) propyl) hydrazono) erythromycin. The reaction mixture is agitated at ambient temperature for one hour. It is poured into water, extracted with ethyl acetate, the aqueous phase is taken up, adjusted to a basic medium, extracted with ethyl acetate, dried, filtered and evaporated to dryness. In this way 271 mg of a product is obtained which is dissolved in ethyl acetate, then sulphuric ether is added until the product crystallizes. After washing with sulphuric ether,
159 mg is obtained which is recrystallized. After drying at 80°C, 120 mg of product melting at 166°C is obtained.
The product 11,12-dideoxy-6-0-methyl-12,11-(oxycarbonyl(2-(3-(4-guinolinyl) propyl) hydrazono) erythromycin was prepared as follows:
STAGE A: Preparation of 11,12-dideoxy 6-O-methyl 12,11-(oxycarbonyl (2-hydrazono)) erythromycin (product P)
a) Condensation
A mixture of 3 g of 10,11-didehydro 11-deoxy 6-O-methyl erythromycin 2'-acetate 12-(IH-imidazole-1-carboxylate 4(phenylmethylcarbonate), 3 ml of hydrazine hydrate, 30 ml of acetonitrile and 492 mg of caesium carbonate is plunged in a bath at 80°C for 10 mn, followed by concentrating to dryness, taking up in methylene chloride, washing with water, drying, filtering and bringing to dryness.
b) Deacetylation g of the product obtained is dissolved in 30 ml of methanol and agitation is carried out at ambient temperature
APh. »8 . 0 13 18
AP 00952 for 15 hours followed by concentrating to dryness. 2.7 g of deacetylated product is obtained,
c) Hydrogenolysis
The product obtained in Stage b) is dissolved in 100 ml 5 of methanol. Hydrogenolysis is carried out in the presence of 600 mg of 10% palladium on activated charcoal, followed by filtering, rinsing with methanol and methylene chloride then the filtrate is concentrated to dryness. 2.52 g of a product is obtained which is purified by eluting with an isopropyl ether-methanol-triethylamine mixture (80-10-10). 941.8 mg of a product is obtained which is chromatographed again eluting with an isopropyl ether-methanol-triethylamine mixture (8010-10). In this way 761 mg of 6-0-methyl-12,11-(oxycarbonyl) (2-hydrazono)) erythromycin is obtained.
Calculated
59.45
8.83
5.33
Found
58.8 8.5 5.2
Microanalysis C%
H%
N%
Mass spectrum
788+ = MH+
810+ = MNa+
STAGE B: 11,12-dideoxy 6-0-methyl 12,ll-(oxycarbonyl-(2-(3(4-quinolinyl) propyl) hydrazono) erythromycin
A mixture of 230 mg of the product obtained in Stage A above, 5 ml of methanol, 0.3 g of quinoline 4-propanal, 0.055 ml of acetic acid is agitated for 15 hours at ambient temperature. 0.065 g of sodium cyanoborohydride is added. Agitation is carried out at ambient temperature for 24 hours. The methanol is evaporated off, followed by extracting with ethyl acetate, washing with a soda solution then with water, drying, filtering’and evaporating to dryness. 220 mg of a product is obtained which is chromatographed on silica, eluting with an ethyl acetate-triethylamine mixture (95-5).
mg of the sought product is obtained.
AP/P/98/0 1 3 18
Microanalysis C%
H%
N%
Calculated
63.99 8.42 5.85
Found
AP 00952 .12
Mass Spectrum
158 + = OH in position 2'
957 + = (M+H) +
979 + = (M+Na)+
EXAMPLE 2; 11,12-dideoxy-3-de ({2,6-dideoxy-3-C-metbyl-3-0methyl-alpha-L-ribohexopyranosyl) oxy) - 3 -hydroxy-6 -0-methyl 12,11-(oxycarbonyl ( (4 - (4-(3-pyridinyl)-1Ξ- imidazol -1-yl) butyl)imino))-erythromycin
By operating as in Example 1 starting with 11,1210 dideoxy-6-O-methyl-12,11-(oxycarbonyl((4-(4-(3-pyridinyl)-1Himidazol-1-yl)butyl)imino))-erythromycin, the sought product was obtained. M.p. = 210°C.
The starting product namely 11,12-dideoxy-6-O-methyl-12,11(oxycarbonyl((4-(4- (3-pyridinyl)-1H-imidazol-1-yl)butyl) imino))-erythromycin was prepared according to the process indicated above for the preparation of the starting product of Example 1.
EXAMPLE OF PHARMACEUTICAL COMPOSITION
Compounds were prepared containing:
Product of Example 1 ...................... 150 mg
Excipient s.q.f.............................. lg
MP/«8/0 13 18
Detail of excipient: starch, talc, magnesium stearate PHARMACOLOGICAL STUDY OF THE PRODUCTS OF THE INVENTION Method of dilutions in liquid medium
A series of tubes were prepared into which the same quantity of sterile nutritive medium is distributed. Increasing quantities of the product to be studied are distributed into each tube, then each tube is seeded with a bacterial strain. After incubation for twenty-four hours in a heating chamber at 37°C, the growth inhibition is evaluated by transillumination, which permits the minimal inhibitory concentrations (M.I.C.) to be determined, expressed in micrograms/cm^.
The following results were obtained:
AP 00952
GRAM+ bacterial strains | ||
Products | Ex. 1 | Ex. 2 |
Staphylococcus aureus 011UC4 Staphylococcus aureus 011G025I Staphylococcus epidermidis 012GO11I | 0.3 | - |
Streptococcus pyogenes group A 02A1UC1 | 0.04 | 0.15 |
Streptococcus agalactiae group B 02B1HT1 | s 0.02 | 0.04 |
Streptococcus faecalis group D 02D2UC1 | 0.04 | 0.3 |
Streptococcus faecium group D 02D3HT1 | 0.04 | 0.3 |
Streptococcus sp group G 02G0GR5 | 0.04 | 0.15 |
Streptococcus mitis 02mitCEl | 0.3 | 0.04 |
Streptococcus mitis 02mitGR16I | 0.15 | 0.6 |
Streptococcus agalactiae group B 02B1SJ1 | 0.6 | 1.2 |
Streptococcus pneumoniae 030SJ5 | 0.6 | 1 |
AP/P/98' 0 1 3 18
Claims (13)
- l) The compounds of formula (I) :in which:X represents a CH2 or S02 radical or an oxygen atom, Y represents a (CE2)m-(CH=CH) n (CH2) o radical, with m+n-f-osS, n = 0 or l,Ar represents an optionally substituted aryl radical,Xi represents a hydrogen atom, !z represents a hydrogen atom or the remainder of an acid, 'well as their addition salts with’acids. '
- 2? The compounds of formula (I) as defined in claim 1, in which S represents a hydrogen atom.
- 3) The compounds of formula (I) as defined in claim l or 2 in which X represents a CH2 radical.'
- 4) The compounds of formula (I) as defined in any one ofAP/P/ 9 8/01318 asAP 00952 claims 1 to 3, in which Y represents a (CH2)3, (CH2)4 or (CE2)5 radical.
- 5) The compounds of formula (I) as defined in any_one of claims 1 to 4, iu which Ar represents a heterocyclic aryl radical..
- 6) The coitiDouads of formula- (±) as defined in any one or claims 1 to 5,-in which Ar represents a 4-quinolinyl radical optionally rr.on.o- or polysubsricuted on one and/or'the other of the 2 quinoline rings.-.
- 7) The compounds of formula (I) as defined in claim 6, in which Ar represents a non-substituted 4-quinolinyl radical. ,
- 8) The compounds of formula (1) as defined in claim 5, in which Ar represents an optionally substituted:81· £ 0 i 8 6 /J/dV radical.
- 9) The compounds of formula (I) as defined in claim l, the names of which follow;-11,12-dideoxy-3-de( (2,6-dideoxy-3-C-methyl-3-O-methyl-alphaL-ribohexopyranosyl) oxy) -3 - hydroxy- 6-O-methyl-12,11(oxycarbonyl { (4- (4- (3-pyridinyl) -IH-imidazol-l-yl) butyl)imino))-erythromycin-11,12-dideoxy-3-de { (2,6-dideoxy-3-C-methyl-3-0-methyl-alphaL-ribohexopyranosyl) oxy)-3-hydroxy-S-0-methyl-12,ll(oxycarbonyl (2- (3- (4-auinolinvl)propyl)hydrazono) ) e ry thr omy c in
- 10) As medicaments, the compounds of formula (1) as defined in any one of claims 1 to 8 as well as their addition salts with pharmaceutically acceptable acids.
- 11) As medicaments the compounds of formula (I) as-defined in claim 9, as well as their addition salts withAP 00952 16 pharmaceutically acceptable acids.
- 12) Pharmaceutical compositions containing at least one medicament according to claim 10 or 11 as active ingredient.
- 13) ι Preparation process for the compounds of formula (I) as5 defined in any one of claims 1 to 9, characterized in that a compound of formula (II) :in which X, Y and Ar are defined as in claim 1, is subjected 25 to the action of a cleavage agent of cladinose in order to obtain the corresponding compound of formula (IA) :AP/P/98 / 0 1 3 18AP 00952 in which X, Y and Ar retain their previous meaning which, if desired, is subjected to the action of an esterification2 0 agent or to the action of an agent capable of introducing the carbamate radical.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9602472A FR2745290B1 (en) | 1996-02-28 | 1996-02-28 | NOVEL ERYTHROMYCIN DERIVATIVES, THEIR PREPARATION PROCESS AND THEIR APPLICATION AS MEDICAMENTS |
PCT/FR1997/000351 WO1997031929A1 (en) | 1996-02-28 | 1997-02-27 | Novel erythromycin derivatives, method for preparing same, and use thereof as drugs |
Publications (2)
Publication Number | Publication Date |
---|---|
AP9801318A0 AP9801318A0 (en) | 1998-09-30 |
AP952A true AP952A (en) | 2001-03-29 |
Family
ID=9489659
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
APAP/P/1998/001318A AP952A (en) | 1996-02-28 | 1997-02-27 | Novel erthromycin derivatives, method for preparing same, and use thereof as drugs. |
Country Status (31)
Country | Link |
---|---|
US (1) | US6096714A (en) |
EP (1) | EP0885234B1 (en) |
JP (1) | JP4102440B2 (en) |
KR (1) | KR100486053B1 (en) |
CN (1) | CN1168734C (en) |
AP (1) | AP952A (en) |
AR (1) | AR005999A1 (en) |
AT (1) | ATE217633T1 (en) |
AU (1) | AU716204B2 (en) |
BG (1) | BG63207B1 (en) |
BR (1) | BR9707709B1 (en) |
CZ (1) | CZ293893B6 (en) |
DE (1) | DE69712610T2 (en) |
DK (1) | DK0885234T3 (en) |
EA (1) | EA001376B1 (en) |
EE (1) | EE9800265A (en) |
ES (1) | ES2176698T3 (en) |
FR (1) | FR2745290B1 (en) |
HU (1) | HU227567B1 (en) |
IL (1) | IL125622A (en) |
NO (1) | NO983955D0 (en) |
NZ (1) | NZ331600A (en) |
OA (1) | OA10845A (en) |
PL (1) | PL191736B1 (en) |
PT (1) | PT885234E (en) |
SK (1) | SK118498A3 (en) |
TR (1) | TR199801713T2 (en) |
UA (1) | UA58504C2 (en) |
WO (1) | WO1997031929A1 (en) |
YU (1) | YU37098A (en) |
ZA (1) | ZA971659B (en) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA989835B (en) * | 1997-10-29 | 1999-05-05 | Taisho Pharmaceutical Co Ltd | Erythromycin a derivatives |
JP2004514643A (en) * | 1997-10-29 | 2004-05-20 | 大正製薬株式会社 | Erythromycin A derivative |
FR2792637B1 (en) * | 1999-04-26 | 2001-06-01 | Hoechst Marion Roussel Inc | NOVEL ERYTHROMYCIN DERIVATIVES, THEIR PREPARATION PROCESS AND THEIR APPLICATION AS MEDICAMENTS |
JP4573925B2 (en) * | 1998-07-09 | 2010-11-04 | アベンティス・ファーマ・ソシエテ・アノニム | Novel erythromycin derivative, its production method and its use as a drug |
FR2780977B1 (en) * | 1998-07-09 | 2000-09-01 | Hoechst Marion Roussel Inc | NOVEL ERYTHROMYCIN DERIVATIVES, THEIR PREPARATION PROCESS AND THEIR APPLICATION AS MEDICAMENTS |
FR2781484B1 (en) | 1998-07-21 | 2001-08-10 | Hoechst Marion Roussel Inc | NOVEL 6-DEOXY ERYTHROMYCIN DERIVATIVES, THEIR PREPARATION PROCESS AND THEIR APPLICATION AS MEDICAMENTS |
HUP0105190A3 (en) | 1999-01-27 | 2003-03-28 | Pfizer Prod Inc | Ketolide antibiotics, medicaments containing them and their use |
JP2003500414A (en) * | 1999-05-24 | 2003-01-07 | ファイザー・プロダクツ・インク | 13-methylerythromycin derivative |
AU6183800A (en) * | 1999-08-06 | 2001-03-05 | Taisho Pharmaceutical Co., Ltd. | Erythromycin a derivatives |
AU6316400A (en) * | 1999-08-06 | 2001-03-05 | Taisho Pharmaceutical Co., Ltd. | Erythromycin a derivatives |
WO2001010878A1 (en) * | 1999-08-06 | 2001-02-15 | Taisho Pharmaceutical Co., Ltd. | Erythromycin a derivatives |
EP1146051A3 (en) * | 2000-04-10 | 2001-10-31 | Pfizer Products Inc. | Erythromycin A derivatives |
US20020115621A1 (en) * | 2000-08-07 | 2002-08-22 | Wei-Gu Su | Macrolide antibiotics |
ITMI20021726A1 (en) * | 2002-08-01 | 2004-02-02 | Zambon Spa | MACROLIDS WITH ANTI-INFLAMMATORY ACTIVITY. |
US7601695B2 (en) | 2003-03-10 | 2009-10-13 | Optimer Pharmaceuticals, Inc. | Antibacterial agents |
WO2005007143A2 (en) * | 2003-07-14 | 2005-01-27 | The Board Of Trustees Of The University Of Illinois | Use of makrolides and ketolides for the treatment of tuberculosis |
WO2007069264A2 (en) * | 2005-12-15 | 2007-06-21 | Alembic Limited | Reference standards for determining the purity of telithromycin and processes therefor |
WO2009055557A1 (en) | 2007-10-25 | 2009-04-30 | Cempra Pharmaceuticals, Inc. | Process for the preparation of macrolide antibacterial agents |
US8796232B2 (en) | 2008-10-24 | 2014-08-05 | Cempra Pharmaceuticals, Inc. | Methods for treating resistant diseases using triazole containing macrolides |
US9937194B1 (en) | 2009-06-12 | 2018-04-10 | Cempra Pharmaceuticals, Inc. | Compounds and methods for treating inflammatory diseases |
JP5914335B2 (en) | 2009-09-10 | 2016-05-11 | センプラ ファーマシューティカルズ,インコーポレイテッド | Method for treating malaria, tuberculosis and MAC disease |
WO2011119604A1 (en) | 2010-03-22 | 2011-09-29 | Cempra Pharmaceuticals, Inc. | Crystalline forms of a macrolide, and uses therefor |
BR112012029586A2 (en) | 2010-05-20 | 2016-08-02 | Cempra Pharmaceuticals Inc | processes for preparing macrolides and ketolides and intermediates thereof |
KR20180110181A (en) | 2010-09-10 | 2018-10-08 | 셈프라 파마슈티컬스, 인크. | Hydrogen bond forming fluoro ketolides for treating diseases |
CA2868262A1 (en) | 2012-03-27 | 2013-10-03 | Cempra Pharmaceuticals, Inc. | Parenteral formulations for administering macrolide antibiotics |
CN105163785A (en) | 2013-03-14 | 2015-12-16 | 森普拉制药公司 | Methods for treating respiratory diseases and formulations therefor |
CA2907085A1 (en) | 2013-03-15 | 2014-09-18 | Cempra Pharmaceuticals, Inc. | Convergent processes for preparing macrolide antibacterial agents |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0487411A1 (en) * | 1990-11-21 | 1992-05-27 | Roussel Uclaf | Erythromycin derivatives, their preparation, intermediates obtained and their application as medicaments |
US5444031A (en) * | 1993-01-21 | 1995-08-22 | Calgon Carbon Corporation | Process for making catalytic carbon |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US487411A (en) * | 1892-12-06 | Island | ||
FR2727969B1 (en) * | 1994-12-09 | 1997-01-17 | Roussel Uclaf | NOVEL ERYTHROMYCIN DERIVATIVES, THEIR PREPARATION PROCESS AND THEIR APPLICATION AS MEDICAMENTS |
-
1996
- 1996-02-28 FR FR9602472A patent/FR2745290B1/en not_active Expired - Lifetime
-
1997
- 1997-02-25 AR ARP970100760A patent/AR005999A1/en unknown
- 1997-02-26 ZA ZA9701659A patent/ZA971659B/en unknown
- 1997-02-27 IL IL12562297A patent/IL125622A/en not_active IP Right Cessation
- 1997-02-27 SK SK1184-98A patent/SK118498A3/en unknown
- 1997-02-27 JP JP53067197A patent/JP4102440B2/en not_active Expired - Lifetime
- 1997-02-27 BR BRPI9707709-7A patent/BR9707709B1/en not_active IP Right Cessation
- 1997-02-27 US US09/125,959 patent/US6096714A/en not_active Ceased
- 1997-02-27 EE EE9800265A patent/EE9800265A/en unknown
- 1997-02-27 ES ES97907141T patent/ES2176698T3/en not_active Expired - Lifetime
- 1997-02-27 TR TR1998/01713T patent/TR199801713T2/en unknown
- 1997-02-27 KR KR10-1998-0706733A patent/KR100486053B1/en not_active IP Right Cessation
- 1997-02-27 AT AT97907141T patent/ATE217633T1/en active
- 1997-02-27 AU AU19298/97A patent/AU716204B2/en not_active Expired
- 1997-02-27 PT PT97907141T patent/PT885234E/en unknown
- 1997-02-27 AP APAP/P/1998/001318A patent/AP952A/en active
- 1997-02-27 EA EA199800768A patent/EA001376B1/en not_active IP Right Cessation
- 1997-02-27 PL PL328608A patent/PL191736B1/en unknown
- 1997-02-27 NZ NZ331600A patent/NZ331600A/en unknown
- 1997-02-27 WO PCT/FR1997/000351 patent/WO1997031929A1/en active IP Right Grant
- 1997-02-27 UA UA98095031A patent/UA58504C2/en unknown
- 1997-02-27 CZ CZ19982587A patent/CZ293893B6/en not_active IP Right Cessation
- 1997-02-27 CN CNB971926255A patent/CN1168734C/en not_active Expired - Lifetime
- 1997-02-27 DK DK97907141T patent/DK0885234T3/en active
- 1997-02-27 DE DE69712610T patent/DE69712610T2/en not_active Expired - Lifetime
- 1997-02-27 EP EP97907141A patent/EP0885234B1/en not_active Expired - Lifetime
- 1997-02-27 HU HU9902576A patent/HU227567B1/en unknown
-
1998
- 1998-08-12 BG BG102691A patent/BG63207B1/en unknown
- 1998-08-27 NO NO983955A patent/NO983955D0/en not_active Application Discontinuation
- 1998-08-28 YU YU37098A patent/YU37098A/en unknown
- 1998-08-28 OA OA9800150A patent/OA10845A/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0487411A1 (en) * | 1990-11-21 | 1992-05-27 | Roussel Uclaf | Erythromycin derivatives, their preparation, intermediates obtained and their application as medicaments |
US5444031A (en) * | 1993-01-21 | 1995-08-22 | Calgon Carbon Corporation | Process for making catalytic carbon |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AP952A (en) | Novel erthromycin derivatives, method for preparing same, and use thereof as drugs. | |
JP3140703B2 (en) | Novel erythromycins, their preparation and use as pharmaceuticals | |
AU697876B2 (en) | New erythromycin derivatives, their preparation process and their use as medicaments | |
JP4573925B2 (en) | Novel erythromycin derivative, its production method and its use as a drug | |
JP5188520B2 (en) | Novel erythromycin derivative, production method and pharmaceutical use | |
AP997A (en) | Novel erythromycin derivatives, method for preparing them and their use as medicine. | |
AP1078A (en) | Novel erythromycin derivatives, method for preparing same and use thereof as drugs. | |
AU728182B2 (en) | New derivatives of erythromycin, their preparation process and their use as medicaments | |
JP4864184B2 (en) | Novel 2-halogenated derivatives of 5-desosaminyl erythronolide A, processes for their preparation and their use as medicaments | |
US5439890A (en) | Erythromycin derivatives | |
USRE38520E1 (en) | Erythromycin derivatives, method for preparing same, and use thereof as drugs | |
AU761551B2 (en) | Novel 6-deoxy erythromycin derivatives, method for preparing same and use as medicines | |
RU2144541C1 (en) | Erythromycin derivatives, method of preparation thereof, intermediate, and pharmaceutical composition | |
MXPA99005226A (en) | Novel erythromycin derivatives, method for preparing them and their use as medicine | |
MXPA99005840A (en) | Novel erythromycin derivatives, method of preparation and application as medicines | |
MXPA99007812A (en) | Novel erythromycin derivatives, method of preparation and application as medicines |